A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age with Chronic Kidney Disease and Hyperkalemia (EMERALD)
Study ID: STU 022017-042
Summary
Please refer to sections 1.4, 2, and 3 of the protocol.